Abstract
Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Current Pharmaceutical Design
Title:Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Volume: 20 Issue: 14
Author(s): Seiji Ueda, Sho-ichi Yamagishi, Miyuki Yokoro and Seiya Okuda
Affiliation:
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Abstract: Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Export Options
About this article
Cite this article as:
Ueda Seiji, Yamagishi Sho-ichi, Yokoro Miyuki and Okuda Seiya, Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990480
DOI https://dx.doi.org/10.2174/13816128113199990480 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination of Irbesartan with Amlodipine Enhances Nitrate/Nitrite Generation by Angiotensin II-exposed Endothelial Cells
Letters in Drug Design & Discovery Factors Influencing Outcome of Patients Receiving Extracorporeal Membrane Oxygenation for Neonatal and Pediatric Respiratory Failure
Current Respiratory Medicine Reviews Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Current Status of Antiplatelet Therapy in Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Leptin and Inflammation
Current Immunology Reviews (Discontinued) Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery Fibrillar, Fibril-associated and Basement Membrane Collagens of the Arterial Wall: Architecture, Elasticity and Remodeling Under Stress
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Safety Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Meet Our Regional Editor Ryuichi Morishita
Current Hypertension Reviews Synthesis and Anxiolytic Activity of Some Novel 5-oxo-1, 4-oxazepine Derivatives
Letters in Drug Design & Discovery